

STEMLINE THERAPEUTICS INC  
Form 8-K  
April 29, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **April 25, 2019**

**Stemline Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35619**  
(Commission File Number)

**45-0522567**  
(IRS Employer Identification No.)

**750 Lexington Avenue**  
**Eleventh Floor**  
**New York, New York 10022**

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

(Address of Principal Executive Offices)

**(646) 502-2311**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act.
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- ☐ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On April 25, 2019, Stemline Therapeutics, Inc. announced that the pivotal trial results of ELZONRIS (tagraxofusp), a targeted therapy directed to CD123, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have been published in the April 25, 2019 issue of the *New England Journal of Medicine*.

ELZONRIS is approved by the U.S. Food and Drug Administration (FDA) for the treatment of BPDCN in adults and pediatric patients two years and older, and is commercially available in the U.S.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit Number	Description
99.1	<u>Press release issued by Stemline Therapeutics, Inc., dated April 25, 2019, announcing <i>New England Journal of Medicine</i> Publication of ELZONRIS (tagraxofusp) Pivotal Study Results .</u>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 29, 2019

**Stemline Therapeutics, Inc.**  
(Registrant)

By

/s/ Kenneth Hoberman  
Kenneth Hoberman  
Chief Operating Officer